<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Target Oncol</journal-id><journal-id journal-id-type="iso-abbrev">Target Oncol</journal-id><journal-title-group><journal-title>Targeted Oncology</journal-title></journal-title-group><issn pub-type="ppub">1776-2596</issn><issn pub-type="epub">1776-260X</issn><publisher><publisher-name>Springer International Publishing</publisher-name><publisher-loc>Cham</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6407750</article-id><article-id pub-id-type="publisher-id">618</article-id><article-id pub-id-type="doi">10.1007/s11523-018-00618-0</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Research Article</subject></subj-group></article-categories><title-group><article-title>Randomized, Open-Label, Crossover Studies Evaluating the Effect of Food and Liquid Formulation on the Pharmacokinetics of the Novel Focal Adhesion Kinase (FAK) Inhibitor BI&#160;853520</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Verheijen</surname><given-names>Remy B.</given-names></name><address><email>r.verheijen@nki.nl</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>van der Biessen</surname><given-names>Diane A. J.</given-names></name><address><email>a.vanderbiessen@erasmusmc.nl</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Hotte</surname><given-names>Sebastien J.</given-names></name><address><email>Hotte@HHSC.CA</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Siu</surname><given-names>Lillian L.</given-names></name><address><email>lillian.siu@uhn.ca</email></address><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Spreafico</surname><given-names>Anna</given-names></name><address><email>anna.spreafico@uhn.ca</email></address><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>de Jonge</surname><given-names>Maja J. A.</given-names></name><address><email>m.dejonge@erasmusmc.nl</email></address><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Pronk</surname><given-names>Linda C.</given-names></name><address><email>linda-christina.pronk@boehringer-ingelheim.com</email></address><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>De Vos</surname><given-names>Filip Y. F. L.</given-names></name><address><email>f.devos@umcutrecht.nl</email></address><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Schnell</surname><given-names>David</given-names></name><address><email>david.schnell@boehringer-ingelheim.com</email></address><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Hirte</surname><given-names>Hal W.</given-names></name><address><email>hirteh@HHSC.CA</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Steeghs</surname><given-names>Neeltje</given-names></name><address><email>n.steeghs@nki.nl</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Lolkema</surname><given-names>Martijn P.</given-names></name><address><phone>+31 10 704 19 06</phone><email>m.lolkema@erasmusmc.nl</email></address><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff5">5</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.430814.a</institution-id><institution>Department of Medical Oncology and Clinical Pharmacology, </institution><institution>Netherlands Cancer Institute, </institution></institution-wrap>Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">000000040459992X</institution-id><institution-id institution-id-type="GRID">grid.5645.2</institution-id><institution>Department of Medical Oncology, </institution><institution>Erasmus MC Cancer Institute, </institution></institution-wrap>Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0408 1469</institution-id><institution-id institution-id-type="GRID">grid.477522.1</institution-id><institution>Division of Medical Oncology, </institution><institution>Juravinski Cancer Centre, </institution></institution-wrap>699 Concession Street, Hamilton, ON L8V 5C2 Canada </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2150 066X</institution-id><institution-id institution-id-type="GRID">grid.415224.4</institution-id><institution>Division of Medical Oncology and Haematology, </institution><institution>Princess Margaret Cancer Centre, </institution></institution-wrap>700 University Avenue, 7th Floor, Toronto, ON M5G 1Z5 Canada </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ISNI">000000040459992X</institution-id><institution-id institution-id-type="GRID">grid.5645.2</institution-id><institution>Department of Internal Oncology, </institution><institution>Erasmus MC Cancer Institute, </institution></institution-wrap>Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands </aff><aff id="Aff6"><label>6</label>Clinical Development Oncology, Boehringer Ingelheim Espa&#241;a S.A., Parque Empresarial Alvento, Via de los Poblados, 1 planta baja-Edif. B ofic. A y C, 28033 Madrid, Spain </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ISNI">0000000090126352</institution-id><institution-id institution-id-type="GRID">grid.7692.a</institution-id><institution>Department of Medical Oncology, </institution><institution>University Medical Center Utrecht Cancer Center, </institution></institution-wrap>Heidelberglaan 100, 3584 CX Utrecht, The Netherlands </aff><aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2171 7500</institution-id><institution-id institution-id-type="GRID">grid.420061.1</institution-id><institution>Department of Translational Medicine and Clinical Pharmacology, </institution><institution>Boehringer Ingelheim Pharma GmbH and Co. KG, </institution></institution-wrap>Birkendorfer Str. 65, 88397 Biberach, Germany </aff></contrib-group><pub-date pub-type="epub"><day>11</day><month>2</month><year>2019</year></pub-date><pub-date pub-type="pmc-release"><day>11</day><month>2</month><year>2019</year></pub-date><pub-date pub-type="ppub"><year>2019</year></pub-date><volume>14</volume><issue>1</issue><fpage>67</fpage><lpage>74</lpage><permissions><copyright-statement>&#169; The Author(s) 2019</copyright-statement><license license-type="OpenAccess"><license-p><bold>OpenAccess</bold>This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par1">BI 853520 is a potent inhibitor of focal adhesion kinase and is currently under clinical development for the treatment of non-hematological malignancies.</p></sec><sec><title>Objective</title><p id="Par2">The objective of this study was to evaluate the effect of food and liquid dispersion on the pharmacokinetics of BI&#160;853520 in two open-label, crossover substudies.</p></sec><sec><title>Patients and Methods</title><p id="Par3">Sixteen patients with advanced solid tumors were enrolled in each substudy. The order of administration was randomized, and pharmacokinetic samples were collected for 48&#160;h after administration of a 200&#160;mg dose of BI&#160;853520. Lack of effect would be demonstrated if the 90% confidence interval (CI) of the ratio of the adjusted geometric mean (GMR) of the area under the plasma curve (area under the plasma concentration&#8211;time curve from time zero to the last quantifiable concentration at <italic>t</italic><sub>z</sub> [<inline-formula id="IEq1"><alternatives><tex-math id="M1">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\text{AUC}}_{{0{-}t_{\text{z}} }}$$\end{document}</tex-math><mml:math id="M2"><mml:msub><mml:mtext>AUC</mml:mtext><mml:mrow><mml:mn>0</mml:mn><mml:mo>-</mml:mo><mml:msub><mml:mi>t</mml:mi><mml:mtext>z</mml:mtext></mml:msub></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="11523_2018_618_Article_IEq1.gif"/></alternatives></inline-formula>] and observed area under the plasma concentration&#8211;time curve extrapolated from time zero to infinity [AUC<sub>0&#8211;&#8734;,obs</sub>]) and maximum plasma concentration (<italic>C</italic><sub>max</sub>) did not cross the 80&#8211;125% (bioequivalence) boundaries.</p></sec><sec><title>Results</title><p id="Par4">Adjusted GMRs (90% CIs) for the fed versus fasted state were 92.46% (74.24&#8211;115.16), 98.17% (78.53&#8211;122.74), and 87.34% (71.04&#8211;107.38) for <inline-formula id="IEq2"><alternatives><tex-math id="M3">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\text{AUC}}_{{0{-}t_{\text{z}} }}$$\end{document}</tex-math><mml:math id="M4"><mml:msub><mml:mtext>AUC</mml:mtext><mml:mrow><mml:mn>0</mml:mn><mml:mo>-</mml:mo><mml:msub><mml:mi>t</mml:mi><mml:mtext>z</mml:mtext></mml:msub></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="11523_2018_618_Article_IEq2.gif"/></alternatives></inline-formula>, AUC<sub>0&#8211;&#8734;,obs</sub>, and <italic>C</italic><sub>max</sub>, respectively. Although the 90% CIs were not within bioequivalence limits for the food-effect study, the limited reductions in these pharmacokinetic parameters after administration with a high-fat meal are unlikely to be clinically relevant. Compared with a tablet, administration of BI&#160;853520 as a liquid dispersion did not strongly affect <inline-formula id="IEq3"><alternatives><tex-math id="M5">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\text{AUC}}_{{0{-}t_{\text{z}} }}$$\end{document}</tex-math><mml:math id="M6"><mml:msub><mml:mtext>AUC</mml:mtext><mml:mrow><mml:mn>0</mml:mn><mml:mo>-</mml:mo><mml:msub><mml:mi>t</mml:mi><mml:mtext>z</mml:mtext></mml:msub></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="11523_2018_618_Article_IEq3.gif"/></alternatives></inline-formula>, AUC<sub>0&#8211;&#8734;,obs</sub>, or <italic>C</italic><sub>max</sub>, resulting in adjusted GMRs (90% CIs) of 1.00 (0.92&#8211;1.09), 0.98 (0.90&#8211;1.07), and 0.93 (0.86&#8211;1.01), respectively.</p></sec><sec><title>Conclusions</title><p id="Par5">These studies demonstrate that BI&#160;853520 can be given with no food restrictions, and as a liquid dispersion, without strongly impacting pharmacokinetics. These pharmacokinetic properties may help make BI&#160;853520 dosing more convenient and flexible, improving treatment compliance.</p></sec><sec><title>Clinical trials registration</title><p>ClinicalTrials.gov identifier: NCT01335269.</p></sec><sec><title>Electronic supplementary material</title><p>The online version of this article (10.1007/s11523-018-00618-0) contains supplementary material, which is available to authorized users.</p></sec></abstract><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100008349</institution-id><institution>Boehringer Ingelheim</institution></institution-wrap></funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; Springer Nature Switzerland AG 2019</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="FPar1"><title>Key Points</title><p id="Par6">
<table-wrap id="Taba"/>
</p></sec><sec id="Sec1"><title>Introduction</title><p id="Par7">Focal adhesion kinase (FAK), also known as protein tyrosine kinase&#160;2 (PTK2), is a non-receptor cytokine tyrosine kinase that comprises a structural component of focal adhesions. These focal adhesions are protein complexes containing cell surface integrins, which are essential for interaction with the extracellular matrix and transduction of signaling pathways [<xref ref-type="bibr" rid="CR1">1</xref>]. FAK plays a vital role in proliferation, survival, and migration of tumor cells [<xref ref-type="bibr" rid="CR2">2</xref>]. In cancer, dysregulation and activation of focal adhesions facilitate cell motility and promote invasive tumor growth [<xref ref-type="bibr" rid="CR1">1</xref>]. Increased expression of FAK is found in various tumor types, and the extent of expression has been related to the extent of disease progression and metastasis [<xref ref-type="bibr" rid="CR3">3</xref>]. In particular, FAK overexpression has been implicated in the development of sarcomas, and prostate, colorectal, ovarian, and breast cancer [<xref ref-type="bibr" rid="CR4">4</xref>&#8211;<xref ref-type="bibr" rid="CR9">9</xref>].</p><p id="Par8">In mice, genetic knockout of FAK has been shown to be embryonically lethal, underscoring its role in development, particularly in the formation of blood vessels [<xref ref-type="bibr" rid="CR10">10</xref>]. Chemical inhibition of FAK has been shown to reduce FAK activity and block tumor growth in a range of xenograft models [<xref ref-type="bibr" rid="CR11">11</xref>&#8211;<xref ref-type="bibr" rid="CR14">14</xref>]. Moreover, inhibition of FAK on endothelial cells has been shown to improve sensitivity of tumor cells to chemotherapy and immunotherapy in preclinical models [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>]. Several inhibitors of FAK have been evaluated in patients with cancer [<xref ref-type="bibr" rid="CR17">17</xref>&#8211;<xref ref-type="bibr" rid="CR19">19</xref>], both as monotherapy and in combination with chemotherapy, targeted and immune therapies [<xref ref-type="bibr" rid="CR20">20</xref>]. BI&#160;853520 is a potent inhibitor of FAK, and clinical exploration has shown target engagement and anti-tumor activity in the phase I studies reported by de Jonge et al. [<xref ref-type="bibr" rid="CR21">21</xref>] and Doi et al. [<xref ref-type="bibr" rid="CR22">22</xref>] in this issue of <italic>Targeted Oncology</italic>. In the study by de Jonge et al. [<xref ref-type="bibr" rid="CR21">21</xref>] involving primarily Caucasian subjects who were dosed in the fasted state, BI&#160;853520 was rapidly absorbed and exhibited at least biphasic disposition kinetics. BI&#160;853520, which is classified as a class 1 drug in the Biopharmaceutics Classification System (BCS), was orally bioavailable, with an observed terminal half-life (<italic>t</italic><sub>&#189;</sub>) of 19&#160;h following administration of a single dose, supporting a once-daily dosing schedule.</p><p id="Par9">A major determinant of drug absorption is the impact of concomitant administration with or without food [<xref ref-type="bibr" rid="CR23">23</xref>]. Food, among other factors, may influence gastric pH, emptying, and motility. Moreover, the presence of a high-fat meal may improve the solubility of lipophilic drugs, thereby increasing (relative) bioavailability. All of these factors can influence the rate and extent of gastrointestinal absorption and indicate the need to study the effects of food on drug bioavailability during clinical drug development [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR25">25</xref>]. A marked influence of food on absorption has been reported for several orally dosed anti-cancer drugs [<xref ref-type="bibr" rid="CR26">26</xref>&#8211;<xref ref-type="bibr" rid="CR29">29</xref>]. In particular, in the case of abiraterone, a 1000% increase in the area under the plasma concentration&#8211;time curve (AUC) was demonstrated when the drug was administered with food compared to a fasted state, illustrating a clinically relevant food effect [<xref ref-type="bibr" rid="CR27">27</xref>].</p><p id="Par10">The requirement to administer drugs in the fasting state can have a major impact on patients&#8217; well-being, especially if the fasting state has to be continued for several hours after drug administration. Further, oral administration of drugs can be problematic for those who cannot swallow whole tablets. This may be particularly relevant in patients with some advanced cancers such as head and neck cancer or esophageal cancer. Therefore, development of an alternative oral formulation could increase the convenience of administration for patients. However, any alternative formulation should be tested clinically first to demonstrate that it achieves appropriate pharmacokinetic exposure.</p><p id="Par11">We report on two randomized, open-label, crossover studies evaluating the effect of administration with or without a high-calorie meal, and the effect of administration as a liquid dispersion on the pharmacokinetics of the novel FAK inhibitor BI&#160;853520. These pharmacokinetic studies were part of a larger phase&#160;I dose-finding trial.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Patients</title><p id="Par12">Patients were eligible for enrollment into the expansion cohorts of the phase&#160;I dose-finding study of BI&#160;853520 (ClinicalTrials.gov identifier NCT01335269; see de Jonge et al. [<xref ref-type="bibr" rid="CR21">21</xref>]) if they had a confirmed diagnosis of advanced, measurable or evaluable, non-resectable and/or metastatic non-hematologic malignancy and disease progression in the last 6&#160;months before study entry as demonstrated by serial imaging. Patients had to have failed conventional treatment or be unamenable to established treatment options, or have no proven therapy available to them. Moreover, patients were required to have an Eastern Cooperative Oncology Group (ECOG) performance score of 0 or 1, have recovered from reversible toxicities (alopecia excluded) from prior anti-cancer therapies (Common Terminology Criteria for Adverse Events grade&#8201;&lt;&#8201;2), be at least 18&#160;years of age, and have a life expectancy of at least 3&#160;months.</p><p id="Par13">The main exclusion criteria were serious concomitant illness, active infections, pregnancy, breastfeeding, active or symptomatic brain metastases, second malignancies, congestive heart failure of grade III or IV, myocardial infarction within 6&#160;months of inclusion, absolute neutrophil count&#8201;&lt;&#8201;1500/mm<sup>3</sup>, platelet count&#8201;&lt;&#8201;100,000/mm<sup>3</sup>, total bilirubin&#8201;&gt;&#8201;1.5 times the upper limit of normal (ULN), and aspartate transferase and/or alanine transferase&#8201;&gt;&#8201;3 times ULN or&#8201;&gt;&#8201;5 times ULN in patients with liver metastases.</p></sec><sec id="Sec4"><title>Study Design</title><p id="Par14">An overview of the design of both studies is provided in Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>. The effect of food on the pharmacokinetics of BI&#160;853520 was investigated in a randomized, open-label, crossover, single-dose study in patients with advanced solid tumors. Patients received a single 200&#160;mg tablet of BI&#160;853520 either in a fed or fasted state (see details of the conditions of drug administration in Sect.&#160;<xref rid="Sec5" ref-type="sec">2.3</xref>) with a washout period of 7&#160;days between each administration. The order of fasted&#8211;fed or fed&#8211;fasted was established through randomization. Further information on the determination of the sample size for each substudy is provided in the Electronic Supplementary Material.<fig id="Fig1"><label>Fig.&#160;1</label><caption><p>Schematic of randomized, open-label, crossover trials to evaluate the effect of food and formulation on the pharmacokinetics of a 200&#160;mg dose of the focal adhesion kinase (FAK) inhibitor BI&#160;853520. The order of administration [fasted&#8211;fed vs. fed&#8211;fasted (<bold>a</bold>) or tablet&#8211;liquid vs. liquid&#8211;tablet (<bold>b</bold>)] was randomized (R), and a washout period of 1&#160;week applied between the two treatments. After the pharmacokinetic studies, patients continued on a daily dose of 200&#160;mg of BI&#160;853520 (as a tablet) until disease progression, intolerability of the study medication, or withdrawal of consent</p></caption><graphic xlink:href="11523_2018_618_Fig1_HTML" id="MO1"/></fig></p><p id="Par15">The pharmacokinetics of a single 200&#160;mg dose of BI&#160;853520 in a liquid dispersion were evaluated in a separate study with the same randomized, open-label, crossover design using the 200&#160;mg tablet as reference. The order of administration (liquid&#8211;tablet or tablet&#8211;liquid) was randomized and a 7-day washout period applied as already described.</p><p id="Par16">After the last pharmacokinetic sample of each pharmacokinetic study, patients continued treatment with a daily dose of 200&#160;mg of BI&#160;853520 until disease progression, intolerability of the study medication, or withdrawal of consent.</p></sec><sec id="Sec5"><title>Drug Administration</title><p id="Par17">In the food-effect study, BI&#160;853520 was administered after an overnight fast, either with approximately 240&#160;mL of water or with a standardized high-calorie meal. No food was allowed for 4&#160;h after intake of the drug. Water was allowed 1&#160;h after taking the drug. The high-calorie meal was a high-fat breakfast containing approximately 950&#160;kcal (at least half of which were from fat) and was ingested within no more than 30&#160;min. Directly after the meal, the single 200&#160;mg tablet of BI&#160;853520 was administered.</p><p id="Par18">In the tablet-versus-liquid formulation study, patients received BI&#160;853520 in a fasted state, as described earlier. Patients remained fasted for 4&#160;h after intake of the drug. The liquid formulation was prepared by dissolution of the tablet in 20&#160;mL of a reconstitution solution containing sucralose (4&#160;mg/mL), menthol (2&#160;mg/mL), and benzoic acid (1&#160;mg/mL). The tablet was submersed in the solution in a child-resistant screw-cap bottle, without being crushed. The bottle was then closed and shaken thoroughly for 30&#160;s. After shaking, the bottle was set aside for 10&#160;min. If the tablet was not dispersed completely, the bottle would be shaken for another 30&#160;s and set aside for 5&#160;min. This procedure was repeated until the tablet was dispersed completely into a homogeneous dispersion without noticeable lumps. No further dilution of the dispersion was allowed.</p></sec><sec id="Sec6"><title>Pharmacokinetic Sampling</title><p id="Par19">In both studies, blood samples were collected before and at 0.5, 1, 2, 3, 4, 6, 8, 10, 24, and 48&#160;h after drug administration. Plasma concentrations of BI&#160;853520 were measured by validated assays based on liquid chromatography coupled to tandem mass spectrometry (LC&#8211;MS/MS). The lower limit of detection for the assay was 1&#160;nM for plasma; at BI&#160;853520 plasma concentrations ranging from 2.5 to 800&#160;ng/mL, precision ranged from &#8722;&#8201;1.6 to &#8722;&#8201;5.1% and accuracy ranged from 5.9 to 11.3%.</p></sec><sec id="Sec7"><title>Data Analysis</title><p id="Par20">Based on the plasma concentration&#8211;time curves, pharmacokinetic parameters were calculated using non-compartmental analysis. Parameters of interest were maximum plasma concentration (<italic>C</italic><sub>max</sub>), time to <italic>C</italic><sub>max</sub> (<italic>t</italic><sub>max</sub>), AUC calculated from time zero to 48&#160;h, from time zero to the last quantifiable concentration at <italic>t</italic><sub>z</sub>, and extrapolated from time zero to infinity (AUC<sub>0&#8211;48</sub>, <inline-formula id="IEq4"><alternatives><tex-math id="M7">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\text{AUC}}_{{0{-}t_{\text{z}} }}$$\end{document}</tex-math><mml:math id="M8"><mml:msub><mml:mtext>AUC</mml:mtext><mml:mrow><mml:mn>0</mml:mn><mml:mo>-</mml:mo><mml:msub><mml:mi>t</mml:mi><mml:mtext>z</mml:mtext></mml:msub></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="11523_2018_618_Article_IEq4.gif"/></alternatives></inline-formula>, and AUC<sub>0&#8211;&#8734;,obs</sub>, respectively) and plasma <italic>t</italic><sub>&#189;</sub> (calculation of <italic>t</italic><sub>&#189;</sub> is described in the Electronic Supplementary Material).</p><p id="Par21">The 90% confidence interval (CI) was calculated for the ratio of the adjusted geometric mean (adjusted GMR) <italic>C</italic><sub>max</sub>, AUC<sub>0&#8211;&#8734;,obs</sub>, and <inline-formula id="IEq5"><alternatives><tex-math id="M9">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\text{AUC}}_{{0{-}t_{\text{z}} }}$$\end{document}</tex-math><mml:math id="M10"><mml:msub><mml:mtext>AUC</mml:mtext><mml:mrow><mml:mn>0</mml:mn><mml:mo>-</mml:mo><mml:msub><mml:mi>t</mml:mi><mml:mtext>z</mml:mtext></mml:msub></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="11523_2018_618_Article_IEq5.gif"/></alternatives></inline-formula> for a 200&#160;mg dose under fed and fasted conditions, and for the 200&#160;mg tablet and liquid formulation. Calculation of an adjusted GMR accounted for sources of variation, such as patients without valid data for both treatment states (fasted and fed) or both formulations (liquid and tablet). Lack of difference was demonstrated if the 90% CI of the adjusted GMRs of <italic>C</italic><sub>max</sub>, AUC<sub>0&#8211;&#8734;,obs</sub>, and <inline-formula id="IEq6"><alternatives><tex-math id="M11">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\text{AUC}}_{{0{-}t_{\text{z}} }}$$\end{document}</tex-math><mml:math id="M12"><mml:msub><mml:mtext>AUC</mml:mtext><mml:mrow><mml:mn>0</mml:mn><mml:mo>-</mml:mo><mml:msub><mml:mi>t</mml:mi><mml:mtext>z</mml:mtext></mml:msub></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="11523_2018_618_Article_IEq6.gif"/></alternatives></inline-formula> were within the 80&#8211;125% limits, in accordance with US Food and Drug Administration (FDA) guidelines for food effect and bioequivalence studies [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR31">31</xref>].</p><p id="Par22">Reasons for exclusion from the pharmacokinetic analysis included vomiting within 4&#160;h after ingestion, failure to take the full BI&#160;853520 dose, and expired sample stability.</p></sec><sec id="Sec8"><title>Trial Conduct and Registry</title><p id="Par23">All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. All patients provided written informed consent before enrollment, in accordance with the International Conference on Harmonization Good Clinical Practice and local legislation. The competent authority that approved the trial was the Centrale Commissie Mensgebonden Onderzoek, Den Haag, The Netherlands. This trial was registered in the United States National Institutes of Health clinical trial registry under the ClinicalTrials.gov identifier NCT01335269.</p></sec></sec><sec id="Sec9"><title>Results</title><p id="Par24">In total, 16 patients were enrolled in each study; patient characteristics are presented in Table&#160;<xref rid="Tab1" ref-type="table">1</xref>. In the food-effect study, 15 patients were evaluable for treatment in at least one state (fed or fasted), and one plasma concentration&#8211;time profile was excluded for one patient due to vomiting after drug administration. In the liquid&#8211;tablet study, all 16 patients were evaluable for treatment with at least one dose (liquid or tablet) of BI&#160;853520, and one plasma concentration&#8211;time profile was excluded for one patient due to incomplete drug administration.<table-wrap id="Tab1"><label>Table&#160;1</label><caption><p>Characteristics of evaluable patients in both studies</p></caption><table-wrap-foot><p><italic>CV</italic> coefficient of variation</p></table-wrap-foot></table-wrap></p><sec id="Sec10"><title>Food Effect</title><p id="Par25">Plasma concentration&#8211;time curves of patients receiving 200&#160;mg of BI&#160;853520 under fed and fasted conditions are presented in Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>. The plasma profile of BI&#160;853520 was not markedly influenced by concomitant administration of the high-calorie meal. A summary of the pharmacokinetic parameters of interest is provided in Table&#160;<xref rid="Tab2" ref-type="table">2</xref>. The adjusted GMRs (90% CIs) for the fed versus fasted state were 92.46% (74.24&#8211;115.16), 98.17% (78.53&#8211;122.74), and 87.34% (71.04&#8211;107.38) for <inline-formula id="IEq7"><alternatives><tex-math id="M13">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\text{AUC}}_{{0{-}t_{\text{z}} }}$$\end{document}</tex-math><mml:math id="M14"><mml:msub><mml:mtext>AUC</mml:mtext><mml:mrow><mml:mn>0</mml:mn><mml:mo>-</mml:mo><mml:msub><mml:mi>t</mml:mi><mml:mtext>z</mml:mtext></mml:msub></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="11523_2018_618_Article_IEq7.gif"/></alternatives></inline-formula>, AUC<sub>0&#8211;&#8734;,obs</sub>, and <italic>C</italic><sub>max</sub>, respectively. All 90% CIs crossed the lower of the 80&#8211;125% boundaries. The <italic>t</italic><sub>max</sub> and <italic>t</italic><sub>&#189;</sub> of BI&#160;853520 administered after a high-calorie meal were not different to those in fasted patients.<fig id="Fig2"><label>Fig.&#160;2</label><caption><p>Plasma concentration&#8211;time curves for BI&#160;853520 (200&#160;mg) in the food-effect and liquid formulation studies. Mean plus standard deviation of the plasma concentration&#8211;time curves for a 200&#160;mg BI&#160;853520 tablet administered to patients in a fed and fasted state (<bold>a</bold>) and a 200&#160;mg dose of BI&#160;853520 administered as a liquid dispersion and tablet (<bold>b</bold>)</p></caption><graphic xlink:href="11523_2018_618_Fig2_HTML" id="MO2"/></fig><table-wrap id="Tab2"><label>Table&#160;2</label><caption><p>Pharmacokinetic parameters for a 200&#160;mg tablet of BI&#160;853520 administered under fed and fasted conditions</p></caption><table-wrap-foot><p>Unless otherwise specified, data are adjusted geometric mean</p><p><italic>AUC</italic><sub><italic>0</italic>&#8211;<italic>&#8734;,obs</italic></sub> observed area under the plasma concentration&#8211;time curve extrapolated from time zero to infinity, <inline-formula id="IEq11"><alternatives><tex-math id="M17">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$AUC_{{0{-}t_{z} }}$$\end{document}</tex-math><mml:math id="M18"><mml:mrow><mml:mi>A</mml:mi><mml:mi>U</mml:mi><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>-</mml:mo><mml:msub><mml:mi>t</mml:mi><mml:mi>z</mml:mi></mml:msub></mml:mrow></mml:msub></mml:mrow></mml:math><inline-graphic xlink:href="11523_2018_618_Article_IEq11.gif"/></alternatives></inline-formula> area under the plasma concentration&#8211;time curve from time zero to the last quantifiable concentration at t<sub>z</sub>, <italic>C</italic><sub><italic>max</italic></sub> maximum plasma concentration, <italic>t</italic><sub>&#189;</sub> terminal half-life, <italic>t</italic><sub><italic>max</italic></sub> time to maximum plasma concentration, &#8211; not calculated</p><p><sup>a</sup>Median [range]</p><p><sup>b</sup>Geometric mean [coefficient of variation (%)]</p><p><sup>c</sup><italic>n&#8201;</italic>=&#8201;14</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec11"><title>Liquid Formulation</title><p id="Par26">Plasma concentration&#8211;time curves for the liquid formulation study are provided in Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>. Calculated parameters for the pharmacokinetics of the liquid dispersion and tablet are presented in Table&#160;<xref rid="Tab3" ref-type="table">3</xref>. The <italic>t</italic><sub>max</sub> and <italic>t</italic><sub>&#189;</sub> were not affected by dispersing BI&#160;853520 in a liquid. Adjusted GMRs (90% CIs) of <inline-formula id="IEq8"><alternatives><tex-math id="M19">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\text{AUC}}_{{0{-}t_{\text{z}} }}$$\end{document}</tex-math><mml:math id="M20"><mml:msub><mml:mtext>AUC</mml:mtext><mml:mrow><mml:mn>0</mml:mn><mml:mo>-</mml:mo><mml:msub><mml:mi>t</mml:mi><mml:mtext>z</mml:mtext></mml:msub></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="11523_2018_618_Article_IEq8.gif"/></alternatives></inline-formula>, AUC<sub>0&#8211;&#8734;,obs</sub>, and <italic>C</italic><sub>max</sub> for the liquid versus tablet formulation were 99.98% (92.28&#8211;108.33), 101.65% (93.57&#8211;110.42), and 107.15% (98.79&#8211;116.22), respectively. All 90% CIs were within the 80&#8211;125% limits, indicating no important impact on pharmacokinetic exposure.<table-wrap id="Tab3"><label>Table&#160;3</label><caption><p>Pharmacokinetic parameters of 200 mg BI 853520 administered as a tablet or liquid formulation</p></caption><table-wrap-foot><p>Unless otherwise specified, data are adjusted geometric mean</p><p><italic>AUC</italic><sub><italic>0</italic>&#8211;<italic>&#8734;,obs</italic></sub> observed area under the plasma concentration&#8211;time curve extrapolated from time zero to infinity, <inline-formula id="IEq13"><alternatives><tex-math id="M23">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$AUC_{{0{-}t_{z} }}$$\end{document}</tex-math><mml:math id="M24"><mml:mrow><mml:mi>A</mml:mi><mml:mi>U</mml:mi><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>-</mml:mo><mml:msub><mml:mi>t</mml:mi><mml:mi>z</mml:mi></mml:msub></mml:mrow></mml:msub></mml:mrow></mml:math><inline-graphic xlink:href="11523_2018_618_Article_IEq13.gif"/></alternatives></inline-formula> area under the plasma concentration&#8211;time curve from time zero to the last quantifiable concentration at <italic>t</italic><sub><italic>z</italic></sub>, <italic>C</italic><sub><italic>max</italic></sub> maximum plasma concentration, <italic>t</italic><sub>&#189;</sub> terminal half-life, <italic>t</italic><sub><italic>max</italic></sub> time to maximum plasma concentration, - indicates not calculated</p><p><sup>a</sup>Median [range]</p><p><sup>b</sup>Geometric mean [coefficient of variation (%)]</p></table-wrap-foot></table-wrap></p></sec></sec><sec id="Sec12"><title>Discussion</title><p id="Par27">The possible effects of food and formulation (liquid dispersion vs. tablet) on pharmacokinetic parameters of BI&#160;853520 were assessed in two randomized, open-label, crossover pharmacokinetic studies. A total of 16 patients were planned for enrollment in each study. This planned sample size was not based on a power calculation, but was judged to be appropriate to achieve the aims of this exploratory substudy, and as being adequate to provide a minimum of 12 evaluable patients for the analysis, as required by FDA guidance.</p><p id="Par28">The plasma profile, <italic>t</italic><sub>max</sub> and <italic>t</italic><sub>&#189;</sub> of BI&#160;853520, when taken after a high-calorie meal, were not markedly different from those in fasted patients. The 90% CI for the adjusted GMRs for <inline-formula id="IEq9"><alternatives><tex-math id="M25">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\text{AUC}}_{{0{-}t_{\text{z}} }}$$\end{document}</tex-math><mml:math id="M26"><mml:msub><mml:mtext>AUC</mml:mtext><mml:mrow><mml:mn>0</mml:mn><mml:mo>-</mml:mo><mml:msub><mml:mi>t</mml:mi><mml:mtext>z</mml:mtext></mml:msub></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="11523_2018_618_Article_IEq9.gif"/></alternatives></inline-formula>, AUC<sub>0&#8211;&#8734;,obs</sub>, and <italic>C</italic><sub>max</sub> all crossed the lower of the 80&#8211;125% boundaries. However, we do not consider the reductions to result in clinically meaningful differences in exposure. Our data, therefore, seem to support the view that BI&#160;853520 may be administered orally without the need for stringent conditions regarding food intake. Interestingly, the geometric mean value for <italic>C</italic><sub>max</sub> decreased slightly when BI&#160;853520 was administered with food (Table&#160;<xref rid="Tab2" ref-type="table">2</xref>), while the median value increased (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>).<fig id="Fig3"><label>Fig.&#160;3</label><caption><p>AUC<sub>0&#8211;48</sub>, AUC<sub>0&#8211;&#8734;,obs</sub>, and <italic>C</italic><sub>max</sub> of BI&#160;853520 (200&#160;mg) in the food-effect and liquid formulation studies. Boxplots of AUC<sub>0&#8211;48</sub>, AUC<sub>0&#8211;&#8734;,obs</sub>, and <italic>C</italic><sub>max</sub> of BI&#160;853520 following a single 200&#160;mg dose administered as a liquid or tablet in the liquid formulation study, and under fed or fasted conditions (both as a tablet) in the food effect study. <italic>AUC</italic><sub><italic>0</italic>&#8211;<italic>&#8734;,obs</italic></sub> observed area under the plasma concentration&#8211;time curve extrapolated from time zero to infinity, <italic>AUC</italic><sub><italic>0</italic>&#8211;<italic>48</italic></sub> area under the plasma concentration&#8211;time curve from time zero to 48&#160;h, <inline-formula id="IEq14"><alternatives><tex-math id="M27">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$AUC_{{0{-}t_{z} }}$$\end{document}</tex-math><mml:math id="M28"><mml:mrow><mml:mi>A</mml:mi><mml:mi>U</mml:mi><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>-</mml:mo><mml:msub><mml:mi>t</mml:mi><mml:mi>z</mml:mi></mml:msub></mml:mrow></mml:msub></mml:mrow></mml:math><inline-graphic xlink:href="11523_2018_618_Article_IEq14.gif"/></alternatives></inline-formula> area under the plasma concentration&#8211;time curve from time zero to the last quantifiable concentration at <italic>t</italic><sub><italic>z</italic></sub>, <italic>C</italic><sub><italic>max</italic></sub> maximum plasma concentration</p></caption><graphic xlink:href="11523_2018_618_Fig3_HTML" id="MO3"/></fig></p><p id="Par29">Administration of BI&#160;853520 after dispersion of the tablet in a reconstitution solvent did not appear to have any clinically important impact on the measured pharmacokinetic parameters. None of the 90% CIs of the calculated pharmacokinetic parameters crossed the predefined 80&#8211;125% limits. This suggests that the bioavailability of BI&#160;853520 is not strongly affected by liquid dispersion and supports the use of the reconstitution liquid to facilitate drug administration in patients who have problems swallowing.</p><p id="Par30">Overall, the results of our study suggest that the pharmacokinetic profile of BI&#160;853520 is unlikely to be greatly influenced by concomitant administration with food or the type of formulation. These properties should allow for a patient-friendly posology, without strict requirements for administration under fasted conditions. In addition, administration of BI&#160;853520 as a liquid dispersion may be particularly convenient for patients who experience problems swallowing.</p><p id="Par31">As is apparent from Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>, we observed large inter-individual pharmacokinetic variability in our study; this was also observed in the dose-finding study (see de Jonge et al. [<xref ref-type="bibr" rid="CR21">21</xref>]). This variability cannot yet be explained; however, it may relate to differing plasma levels of &#945;-1-acid glycoprotein (AGP), the major binding partner of BI&#160;853520 in human plasma.</p></sec><sec id="Sec13"><title>Conclusion</title><p id="Par32">These randomized, open-label, crossover studies suggest that a high-calorie meal did not appear to have a large impact on BI&#160;853520 pharmacokinetics. Further, our data suggest that the formulation of BI&#160;853520 as a liquid dispersion has no important effects on the pharmacokinetics of BI&#160;853520 relative to the tablet formulation. These pharmacokinetic properties may help make BI&#160;853520 dosing more convenient and flexible, improving treatment compliance.</p></sec><sec sec-type="supplementary-material"><title>Electronic supplementary material</title><sec id="Sec14"><p>Below is the link to the electronic supplementary material.
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="11523_2018_618_MOESM1_ESM.pdf"><caption><p>Supplementary material 1 (PDF 111&#160;kb)</p></caption></media></supplementary-material></p></sec></sec></body><back><notes notes-type="funding"><sec id="FPar2"><title>Funding</title><p>This work was supported by Boehringer Ingelheim, Ingelheim am Rhein, Germany. BI&#160;853520 is an asset of Boehringer Ingelheim. This article was published open access under a Springer Compact agreement with Dutch universities and Academy institutes.</p></sec></notes><ack><title>Acknowledgements</title><p>Medical writing and editing assistance, supported financially by Boehringer Ingelheim, was provided by Lynn Pritchard of GeoMed, an Ashfield Company, part of UDG Healthcare plc, during the preparation of this article.</p></ack><notes notes-type="COI-statement"><sec id="FPar3"><title>Conflict of interest</title><p>Remy B. Verheijen is an employee of AstraZeneca. Lillian L. Siu reports clinical trial funding (for her institution) for this study provided by from Boehringer Ingelheim. Linda C. Pronk and David Schnell are employees of Boehringer Ingelheim. Filip Y. F. L. De Vos has been paid for expert testimonial by Bristol-Myers Squibb, and received grants from Novartis. Hal W. Hirte has received honoraria from&#160;AstraZeneca, Roche, and Merck. Diane A. J. van der Biessen, Sebastien J. Hotte, Anna Spreafico, Maja J. A. de Jonge, Neeltje Steeghs, and Martijn P. Lolkema declare no conflicts of interest.</p></sec></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lim</surname><given-names>ST</given-names></name><name><surname>Mikolon</surname><given-names>D</given-names></name><name><surname>Stupack</surname><given-names>DG</given-names></name><name><surname>Schlaepfer</surname><given-names>DD</given-names></name></person-group><article-title>FERM control of FAK function: implications for cancer therapy</article-title><source>Cell Cycle</source><year>2008</year><volume>7</volume><issue>15</issue><fpage>2306</fpage><lpage>2314</lpage><pub-id pub-id-type="doi">10.4161/cc.6367</pub-id><pub-id pub-id-type="pmid">18677107</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Hochwald</surname><given-names>SN</given-names></name></person-group><article-title>The role of FAK in tumor metabolism and therapy</article-title><source>Pharmacol Ther</source><year>2014</year><volume>142</volume><issue>2</issue><fpage>154</fpage><lpage>163</lpage><pub-id pub-id-type="doi">10.1016/j.pharmthera.2013.12.003</pub-id><pub-id pub-id-type="pmid">24333503</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sulzmaier</surname><given-names>FJ</given-names></name><name><surname>Jean</surname><given-names>C</given-names></name><name><surname>Schlaepfer</surname><given-names>DD</given-names></name></person-group><article-title>FAK in cancer: mechanistic findings and clinical applications</article-title><source>Nat Rev Cancer</source><year>2014</year><volume>14</volume><issue>9</issue><fpage>598</fpage><lpage>610</lpage><pub-id pub-id-type="doi">10.1038/nrc3792</pub-id><pub-id pub-id-type="pmid">25098269</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oktay</surname><given-names>MH</given-names></name><name><surname>Oktay</surname><given-names>K</given-names></name><name><surname>Hamele-Bena</surname><given-names>D</given-names></name><name><surname>Buyuk</surname><given-names>A</given-names></name><name><surname>Koss</surname><given-names>LG</given-names></name></person-group><article-title>Focal adhesion kinase as a marker of malignant phenotype in breast and cervical carcinomas</article-title><source>Hum Pathol</source><year>2003</year><volume>34</volume><issue>3</issue><fpage>240</fpage><lpage>245</lpage><pub-id pub-id-type="doi">10.1053/hupa.2003.40</pub-id><pub-id pub-id-type="pmid">12673558</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Owens</surname><given-names>LV</given-names></name><name><surname>Xu</surname><given-names>L</given-names></name><name><surname>Craven</surname><given-names>RJ</given-names></name><name><surname>Dent</surname><given-names>GA</given-names></name><name><surname>Weiner</surname><given-names>TM</given-names></name><name><surname>Kornberg</surname><given-names>L</given-names></name><etal/></person-group><article-title>Overexpression of the focal adhesion kinase (p125FAK) in invasive human tumors</article-title><source>Cancer Res</source><year>1995</year><volume>55</volume><issue>13</issue><fpage>2752</fpage><lpage>2755</lpage><pub-id pub-id-type="pmid">7796399</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lark</surname><given-names>AL</given-names></name><name><surname>Livasy</surname><given-names>CA</given-names></name><name><surname>Calvo</surname><given-names>B</given-names></name><name><surname>Caskey</surname><given-names>L</given-names></name><name><surname>Moore</surname><given-names>DT</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><etal/></person-group><article-title>Overexpression of focal adhesion kinase in primary colorectal carcinomas and colorectal liver metastases: immunohistochemistry and real-time PCR analyses</article-title><source>Clin Cancer Res</source><year>2003</year><volume>9</volume><issue>1</issue><fpage>215</fpage><lpage>222</lpage><pub-id pub-id-type="pmid">12538472</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Judson</surname><given-names>PL</given-names></name><name><surname>He</surname><given-names>X</given-names></name><name><surname>Cance</surname><given-names>WG</given-names></name><name><surname>Van Le</surname><given-names>L</given-names></name></person-group><article-title>Overexpression of focal adhesion kinase, a protein tyrosine kinase, in ovarian carcinoma</article-title><source>Cancer</source><year>1999</year><volume>86</volume><issue>8</issue><fpage>1551</fpage><lpage>1556</lpage><pub-id pub-id-type="doi">10.1002/(SICI)1097-0142(19991015)86:6&lt;1551::AID-CNCR23&gt;3.0.CO;2-P</pub-id><pub-id pub-id-type="pmid">10526262</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tremblay</surname><given-names>L</given-names></name><name><surname>Hauck</surname><given-names>W</given-names></name><name><surname>Aprikian</surname><given-names>AG</given-names></name><name><surname>Begin</surname><given-names>LR</given-names></name><name><surname>Chapdelaine</surname><given-names>A</given-names></name><name><surname>Chevalier</surname><given-names>S</given-names></name></person-group><article-title>Focal adhesion kinase (pp125FAK) expression, activation and association with paxillin and p50CSK in human metastatic prostate carcinoma</article-title><source>Int J Cancer</source><year>1996</year><volume>68</volume><issue>2</issue><fpage>164</fpage><lpage>171</lpage><pub-id pub-id-type="doi">10.1002/(SICI)1097-0215(19961009)68:2&lt;169::AID-IJC4&gt;3.0.CO;2-W</pub-id><pub-id pub-id-type="pmid">8900422</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weiner</surname><given-names>TM</given-names></name><name><surname>Liu</surname><given-names>ET</given-names></name><name><surname>Craven</surname><given-names>RJ</given-names></name><name><surname>Cance</surname><given-names>WG</given-names></name></person-group><article-title>Expression of focal adhesion kinase gene and invasive cancer</article-title><source>Lancet</source><year>1993</year><volume>342</volume><issue>8878</issue><fpage>1024</fpage><lpage>1025</lpage><pub-id pub-id-type="doi">10.1016/0140-6736(93)92881-S</pub-id><pub-id pub-id-type="pmid">8105266</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ilic</surname><given-names>D</given-names></name><name><surname>Kovacic</surname><given-names>B</given-names></name><name><surname>McDonagh</surname><given-names>S</given-names></name><name><surname>Jin</surname><given-names>F</given-names></name><name><surname>Baumbusch</surname><given-names>C</given-names></name><name><surname>Gardner</surname><given-names>DG</given-names></name><etal/></person-group><article-title>Focal adhesion kinase is required for blood vessel morphogenesis</article-title><source>Circ Res</source><year>2003</year><volume>92</volume><issue>3</issue><fpage>300</fpage><lpage>307</lpage><pub-id pub-id-type="doi">10.1161/01.RES.0000055016.36679.23</pub-id><pub-id pub-id-type="pmid">12595342</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Golubovskaya</surname><given-names>VM</given-names></name><name><surname>Figel</surname><given-names>S</given-names></name><name><surname>Ho</surname><given-names>BT</given-names></name><name><surname>Johnson</surname><given-names>CP</given-names></name><name><surname>Yemma</surname><given-names>M</given-names></name><name><surname>Huang</surname><given-names>G</given-names></name><etal/></person-group><article-title>A small molecule focal adhesion kinase (FAK) inhibitor, targeting Y397 site: 1-(2-hydroxyethyl)-3, 5, 7-triaza-1-azoniatricyclo [3.3.1.1(3,7)]decane; bromide effectively inhibits FAK autophosphorylation activity and decreases cancer cell viability, clonogenicity and tumor growth in vivo</article-title><source>Carcinogenesis</source><year>2012</year><volume>33</volume><issue>5</issue><fpage>1004</fpage><lpage>1013</lpage><pub-id pub-id-type="doi">10.1093/carcin/bgs120</pub-id><pub-id pub-id-type="pmid">22402131</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Golubovskaya</surname><given-names>VM</given-names></name><name><surname>Ho</surname><given-names>B</given-names></name><name><surname>Zheng</surname><given-names>M</given-names></name><name><surname>Magis</surname><given-names>A</given-names></name><name><surname>Ostrov</surname><given-names>D</given-names></name><name><surname>Morrison</surname><given-names>C</given-names></name><etal/></person-group><article-title>Disruption of focal adhesion kinase and p53 interaction with small molecule compound R2 reactivated p53 and blocked tumor growth</article-title><source>BMC Cancer</source><year>2013</year><volume>13</volume><fpage>342</fpage><pub-id pub-id-type="doi">10.1186/1471-2407-13-342</pub-id><pub-id pub-id-type="pmid">23841915</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walsh</surname><given-names>C</given-names></name><name><surname>Tanjoni</surname><given-names>I</given-names></name><name><surname>Uryu</surname><given-names>S</given-names></name><name><surname>Tomar</surname><given-names>A</given-names></name><name><surname>Nam</surname><given-names>JO</given-names></name><name><surname>Luo</surname><given-names>H</given-names></name><etal/></person-group><article-title>Oral delivery of PND-1186 FAK inhibitor decreases tumor growth and spontaneous breast to lung metastasis in pre-clinical models</article-title><source>Cancer Biol Ther</source><year>2010</year><volume>9</volume><issue>10</issue><fpage>778</fpage><lpage>790</lpage><pub-id pub-id-type="doi">10.4161/cbt.9.10.11433</pub-id><pub-id pub-id-type="pmid">20234193</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roberts</surname><given-names>WG</given-names></name><name><surname>Ung</surname><given-names>E</given-names></name><name><surname>Whalen</surname><given-names>P</given-names></name><name><surname>Cooper</surname><given-names>B</given-names></name><name><surname>Hulford</surname><given-names>C</given-names></name><name><surname>Autry</surname><given-names>C</given-names></name><etal/></person-group><article-title>Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271</article-title><source>Cancer Res</source><year>2008</year><volume>68</volume><issue>6</issue><fpage>1935</fpage><lpage>1944</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-07-5155</pub-id><pub-id pub-id-type="pmid">18339875</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tavora</surname><given-names>B</given-names></name><name><surname>Reynolds</surname><given-names>LE</given-names></name><name><surname>Batista</surname><given-names>S</given-names></name><name><surname>Demircioglu</surname><given-names>F</given-names></name><name><surname>Fernandez</surname><given-names>I</given-names></name><name><surname>Lechertier</surname><given-names>T</given-names></name><etal/></person-group><article-title>Endothelial-cell FAK targeting sensitizes tumours to DNA-damaging therapy</article-title><source>Nature</source><year>2014</year><volume>514</volume><issue>7520</issue><fpage>112</fpage><lpage>116</lpage><pub-id pub-id-type="doi">10.1038/nature13541</pub-id><pub-id pub-id-type="pmid">25079333</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>H</given-names></name><name><surname>Hegde</surname><given-names>S</given-names></name><name><surname>Knolhoff</surname><given-names>BL</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Herndon</surname><given-names>JM</given-names></name><name><surname>Meyer</surname><given-names>MA</given-names></name><etal/></person-group><article-title>Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy</article-title><source>Nat Med</source><year>2016</year><volume>22</volume><issue>8</issue><fpage>851</fpage><lpage>860</lpage><pub-id pub-id-type="doi">10.1038/nm.4123</pub-id><pub-id pub-id-type="pmid">27376576</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>SF</given-names></name><name><surname>Siu</surname><given-names>LL</given-names></name><name><surname>Bendell</surname><given-names>JC</given-names></name><name><surname>Cleary</surname><given-names>JM</given-names></name><name><surname>Razak</surname><given-names>AR</given-names></name><name><surname>Infante</surname><given-names>JR</given-names></name><etal/></person-group><article-title>A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors</article-title><source>Investig New Drugs</source><year>2015</year><volume>33</volume><issue>5</issue><fpage>1100</fpage><lpage>1107</lpage><pub-id pub-id-type="doi">10.1007/s10637-015-0282-y</pub-id><pub-id pub-id-type="pmid">26334219</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Infante</surname><given-names>JR</given-names></name><name><surname>Camidge</surname><given-names>DR</given-names></name><name><surname>Mileshkin</surname><given-names>LR</given-names></name><name><surname>Chen</surname><given-names>EX</given-names></name><name><surname>Hicks</surname><given-names>RJ</given-names></name><name><surname>Rischin</surname><given-names>D</given-names></name><etal/></person-group><article-title>Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors</article-title><source>J Clin Oncol</source><year>2012</year><volume>30</volume><issue>13</issue><fpage>1527</fpage><lpage>1533</lpage><pub-id pub-id-type="doi">10.1200/JCO.2011.38.9346</pub-id><pub-id pub-id-type="pmid">22454420</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soria</surname><given-names>JC</given-names></name><name><surname>Gan</surname><given-names>HK</given-names></name><name><surname>Blagden</surname><given-names>SP</given-names></name><name><surname>Plummer</surname><given-names>R</given-names></name><name><surname>Arkenau</surname><given-names>HT</given-names></name><name><surname>Ranson</surname><given-names>M</given-names></name><etal/></person-group><article-title>A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors</article-title><source>Ann Oncol</source><year>2016</year><volume>27</volume><issue>12</issue><fpage>2268</fpage><lpage>2274</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdw427</pub-id><pub-id pub-id-type="pmid">27733373</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roy-Luzarraga</surname><given-names>M</given-names></name><name><surname>Hodivala-Dilke</surname><given-names>K</given-names></name></person-group><article-title>Molecular pathways: endothelial cell FAK-A target for cancer treatment</article-title><source>Clin Cancer Res</source><year>2016</year><volume>22</volume><issue>15</issue><fpage>3718</fpage><lpage>3724</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-14-2021</pub-id><pub-id pub-id-type="pmid">27262114</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Jonge</surname><given-names>MJA</given-names></name><name><surname>Steeghs</surname><given-names>N</given-names></name><name><surname>Lolkema</surname><given-names>MP</given-names></name><name><surname>Hotte</surname><given-names>SJ</given-names></name><name><surname>Hirte</surname><given-names>HW</given-names></name><name><surname>van der Biessen</surname><given-names>Diane AJ</given-names></name><etal/></person-group><article-title>Phase I study of BI 853520, an inhibitor of focal adhesion kinase, in patients with advanced or metastatic nonhematologic malignancies</article-title><source>Target Oncol.</source><year>2019</year></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doi</surname><given-names>T</given-names></name><name><surname>Yang</surname><given-names>JC-H</given-names></name><name><surname>Shitara</surname><given-names>K</given-names></name><name><surname>Naito</surname><given-names>Y</given-names></name><name><surname>Cheng</surname><given-names>A-L</given-names></name><name><surname>Sarashina</surname><given-names>A</given-names></name><etal/></person-group><article-title>Phase I study of the focal adhesion kinase inhibitor BI 853520 in Japanese and Taiwanese patients with advanced or metastatic solid tumors</article-title><source>Target Oncol.</source><year>2019</year></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>BN</given-names></name><name><surname>Malhotra</surname><given-names>BK</given-names></name></person-group><article-title>Effects of food on the clinical pharmacokinetics of anticancer agents: underlying mechanisms and implications for oral chemotherapy</article-title><source>Clin Pharmacokinet</source><year>2004</year><volume>43</volume><issue>15</issue><fpage>1127</fpage><lpage>1156</lpage><pub-id pub-id-type="doi">10.2165/00003088-200443150-00005</pub-id><pub-id pub-id-type="pmid">15568891</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parsad</surname><given-names>S</given-names></name><name><surname>Ratain</surname><given-names>MJ</given-names></name></person-group><article-title>Food effect studies for oncology drug products</article-title><source>Clin Pharmacol Ther</source><year>2017</year><volume>101</volume><issue>5</issue><fpage>606</fpage><lpage>612</lpage><pub-id pub-id-type="doi">10.1002/cpt.610</pub-id><pub-id pub-id-type="pmid">28073144</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szmulewitz</surname><given-names>RZ</given-names></name><name><surname>Ratain</surname><given-names>MJ</given-names></name></person-group><article-title>Playing Russian roulette with tyrosine kinase inhibitors</article-title><source>Clin Pharmacol Ther</source><year>2013</year><volume>93</volume><issue>3</issue><fpage>242</fpage><lpage>244</lpage><pub-id pub-id-type="doi">10.1038/clpt.2012.245</pub-id><pub-id pub-id-type="pmid">23340477</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heath</surname><given-names>EI</given-names></name><name><surname>Chiorean</surname><given-names>EG</given-names></name><name><surname>Sweeney</surname><given-names>CJ</given-names></name><name><surname>Hodge</surname><given-names>JP</given-names></name><name><surname>Lager</surname><given-names>JJ</given-names></name><name><surname>Forman</surname><given-names>K</given-names></name><etal/></person-group><article-title>A phase I study of the pharmacokinetic and safety profiles of oral pazopanib with a high-fat or low-fat meal in patients with advanced solid tumors</article-title><source>Clin Pharmacol Ther</source><year>2010</year><volume>88</volume><issue>6</issue><fpage>818</fpage><lpage>823</lpage><pub-id pub-id-type="doi">10.1038/clpt.2010.199</pub-id><pub-id pub-id-type="pmid">20980999</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chi</surname><given-names>KN</given-names></name><name><surname>Spratlin</surname><given-names>J</given-names></name><name><surname>Kollmannsberger</surname><given-names>C</given-names></name><name><surname>North</surname><given-names>S</given-names></name><name><surname>Pankras</surname><given-names>C</given-names></name><name><surname>Gonzalez</surname><given-names>M</given-names></name><etal/></person-group><article-title>Food effects on abiraterone pharmacokinetics in healthy subjects and patients with metastatic castration-resistant prostate cancer</article-title><source>J Clin Pharmacol</source><year>2015</year><volume>55</volume><issue>12</issue><fpage>1406</fpage><lpage>1414</lpage><pub-id pub-id-type="doi">10.1002/jcph.564</pub-id><pub-id pub-id-type="pmid">26096139</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kovarik</surname><given-names>JM</given-names></name><name><surname>Hartmann</surname><given-names>S</given-names></name><name><surname>Figueiredo</surname><given-names>J</given-names></name><name><surname>Rordorf</surname><given-names>C</given-names></name><name><surname>Golor</surname><given-names>G</given-names></name><name><surname>Lison</surname><given-names>A</given-names></name><etal/></person-group><article-title>Effect of food on everolimus absorption: quantification in healthy subjects and a confirmatory screening in patients with renal transplants</article-title><source>Pharmacotherapy</source><year>2002</year><volume>22</volume><issue>2</issue><fpage>154</fpage><lpage>159</lpage><pub-id pub-id-type="doi">10.1592/phco.22.3.154.33542</pub-id><pub-id pub-id-type="pmid">11837553</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koch</surname><given-names>KM</given-names></name><name><surname>Reddy</surname><given-names>NJ</given-names></name><name><surname>Cohen</surname><given-names>RB</given-names></name><name><surname>Lewis</surname><given-names>NL</given-names></name><name><surname>Whitehead</surname><given-names>B</given-names></name><name><surname>Mackay</surname><given-names>K</given-names></name><etal/></person-group><article-title>Effects of food on the relative bioavailability of lapatinib in cancer patients</article-title><source>J Clin Oncol</source><year>2009</year><volume>27</volume><issue>8</issue><fpage>1191</fpage><lpage>1196</lpage><pub-id pub-id-type="doi">10.1200/JCO.2008.18.3285</pub-id><pub-id pub-id-type="pmid">19188677</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><mixed-citation publication-type="other">Food and Drug Administration. Guidance for Industry. Food-effect bioavailability and fed bioequivalance studies. 2002. <ext-link ext-link-type="uri" xlink:href="https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm070241.pdf">https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm070241.pdf</ext-link>. Accessed 21 Dec 2018.</mixed-citation></ref><ref id="CR31"><label>31.</label><mixed-citation publication-type="other">Food and Drug Administration. Bioavailability and bioequivalence studies submitted in NDAs or INDs - general considerations (draft). 2014. <ext-link ext-link-type="uri" xlink:href="https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm389370.pdf">https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm389370.pdf</ext-link>. Accessed 21 Dec 2018.</mixed-citation></ref></ref-list></back></article>